Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Ardelyx (Nasdaq: ARDX) will report third quarter 2025 financial results and provide a business update on Thursday, October 30, 2025 at 4:30 p.m. ET.

Rhea-AI Summary

Ardelyx (Nasdaq: ARDX) will report third quarter 2025 financial results and provide a business update on Thursday, October 30, 2025 at 4:30 p.m. ET. The company will host a live conference call and simultaneous webcast accessible from the Investors section of its website at www.ardelyx.com. Domestic dial-in is (877) 346-6112 and international dial-in is (848) 280-6350. The live webcast will be archived and available for replay for 30 days after the call.

Argus Oct 13 session

+1.42% close to close Open Argus

Details

News Market Reaction – ARDX

On Oct 13, the day this news came out, ARDX closed 1.42% above the previous close.

Data tracked by StockTitan Argus for the Oct 13 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference call scheduled for 4:30 p.m. Eastern Time

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, October 30, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the third quarter of 2025.

To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

About Ardelyx

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Ardelyx (ARDX) report third quarter 2025 results?

Ardelyx will report results and hold a conference call on October 30, 2025 at 4:30 p.m. ET.

How can investors join the Ardelyx (ARDX) October 30, 2025 conference call?

Dial (877) 346-6112 (U.S.) or (848) 280-6350 (international) and request to join the Ardelyx call.

Where can I listen to the Ardelyx (ARDX) Q3 2025 webcast?

The live webcast will be available under the Investors section at www.ardelyx.com.

Will the Ardelyx (ARDX) Q3 2025 webcast be available after the call and for how long?

Yes. The webcast will be archived and available for replay for 30 days following the call.

What time is the Ardelyx (ARDX) earnings call for investors in Eastern Time?

The earnings call is scheduled for 4:30 p.m. Eastern Time on October 30, 2025.